Myeloproliferative Neoplasms
Myeloproliferative Neoplasms
The latest news, research, and perspectives in myeloproliferative neoplasms (MPNs). MPNs occur when the bone marrow produces too many red blood cells, platelets, or certain white blood cells. The primary subtypes include myelofibrosis, polycythemia vera, and essential thrombocythemia.
Sangeetha Venugopal, MDMyelofibrosis | September 20, 2023
Myelofibrosis Awareness Day is marked on September 20th each year.
View More
Leah LawrenceMeeting News | September 19, 2023
Researchers presented updated data from the phase I XPORT-MF-034 trial at the Eleventh SOHO Annual Meeting.
Leah LawrenceMyelofibrosis | September 19, 2023
The open-label ACE-536-MF-001 study included patient cohorts grouped by transfusion dependance and ruxolitinib therapy.
Leah LawrenceMyelofibrosis | September 18, 2023
In PERSIST-2, treatment with pacritinib demonstrated a significant SVR benefit compared with the best available therapy, incl
Leah SherwoodMyelofibrosis | September 16, 2023
Nearly all myelofibrosis patients are estimated to develop anemia over the course of the disease.
Cailin ConnerMeeting News | September 10, 2023
The need for phlebotomies substantially decreased in those who received ruxolitinib after hydroxyurea.
Cailin ConnerMeeting News | September 10, 2023
The combined average cost for the index hospitalization and two-year TE-related readmissions was $30,285.
Cecilia BrownMeeting News | September 9, 2023
Patients with MPNs faced higher direct and indirect costs and were significantly more likely to take disability leave.
Cailin ConnerPolycythemia Vera | September 9, 2023
The investigators sought to investigate the diagnostic landscape of polycythemia vera in LMICs.
Cecilia BrownMyeloproliferative Neoplasms | September 9, 2023
Researchers presented data from the randomized withdrawal phase of the study at the SOHO Annual Meeting.
Cecilia BrownMyelofibrosis | August 21, 2023
Ruxolitinib, an oral JAK1/JAK2 inhibitor, initially received FDA approval in 2011.
Cecilia BrownMyelofibrosis | August 21, 2023
Researchers conducted the study because the mechanism by which pacritinib improves anemia has not been elucidated.
Cecilia BrownMyelofibrosis | August 18, 2023
Researchers conducted an indirect comparison analysis of multiple clinical trials to address the question.
Leah SherwoodMyelofibrosis | August 9, 2023
In June 2023, the manufacturer of the drug initiated XPORT-MF-034, a pivotal phase III clinical trial.
Leah SherwoodAcute Myeloid Leukemia | July 17, 2023
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
Cecilia BrownMyelofibrosis | July 14, 2023
At a median follow-up of 55 weeks, 90% of patients completed 24 weeks of treatment and 56% completed 48 weeks of treatment.
Cecilia BrownMyelofibrosis | July 13, 2023
Initiation of ruxolitinib therapy within two years of diagnosis was associated with increased response rates in all patients.
Leah SherwoodPolycythemia Vera | July 6, 2023
Dr. Harrison discusses survey results from the LANDMARK survey in patients with polycythemia vera and their physicians.
Cecilia BrownMyeloproliferative Neoplasms | June 20, 2023
Just under half (43%) of patients receiving ruxolitinib achieved a CR, while 26% achieved a CR on the best available therapy.
Cecilia BrownPolycythemia Vera | June 19, 2023
The trial included patients with PV who had at least three therapeutic phlebotomies in the 28 weeks prior to enrollment.
Editorial Board